News
CSL’s first gene therapy for haemophilia B approved
CSL has revealed that the European Commission (EC) has granted conditional marketing authorisation for HEMGENIX.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
CSL has revealed that the European Commission (EC) has granted conditional marketing authorisation for HEMGENIX.